AI reduces reading workload by nearly half while detecting more breast cancers in MASAI study
Of everything promised about artificial intelligence in medicine, one case has completed the full course: randomised trial, prespecified primary endpoint, published result. It is breast cancer screening, and the trial is called MASAI. With 105,934 women randomised within Sweden's national programme, AI-supported reading detected 29% more cancers than standard double reading, without increasing false positives, and cut reading workload by 44%. And in 2026 came the missing figure: interval cancers, the endpoint that actually measures whether a screening programme is safe. This article explains why this case counts and what sets it apart.The 30-second summary: the seven figures that matterEach…
